5-Amino-1MQ Guide: Dosage, Fat Loss Mechanism & NNMT Explained
5-Amino-1MQ
5-Amino-1MQ is a small-molecule compound studied for metabolic health, body composition, and cellular energy regulation. It works by inhibiting NNMT (nicotinamide N-methyltransferase), an enzyme involved in cellular metabolism and energy balance.
How It Works
NNMT Inhibition ↓ → NAD+ Metabolism Pathways ↑ → Cellular Energy Signaling ↑ → Metabolic Research Interest
5-Amino-1MQ inhibits NNMT, an enzyme associated with fat accumulation and metabolic inefficiency. By reducing NNMT activity, it may improve cellular energy utilization and shift the body toward increased fat metabolism.
Important Distinction
5-Amino-1MQ is not a peptide.
It is a small-molecule metabolic research compound.
It works through NNMT inhibition, not hormone signaling pathways.
Injectable 5-Amino-1MQ Reconstitution & Dosing
Injectable 5-Amino-1MQ → BAC Water → SubQ Research Use → Lower mg Range Than Oral
Important distinction:
5-Amino-1MQ is still most commonly discussed as an oral compound, but injectable research vials do exist. Injectable dosing should not be directly compared to oral dosing because the route changes exposure and practical dose ranges.
5-Amino-1MQ is still most commonly discussed as an oral compound, but injectable research vials do exist. Injectable dosing should not be directly compared to oral dosing because the route changes exposure and practical dose ranges.
Common Injectable Vial Sizes
Smaller Vial10 mg
Larger Vial50 mg
The 50 mg vial is usually more practical for multi-day use because injectable doses are commonly discussed in the low-mg range.
Vial sizes vary by supplier and formulation.
10 mg Vial Option
Vial10 mg
BAC Water2.0 mL
Concentration5 mg/mL
Conversion1 unit = 50 mcg
Dose Reference
50 units = 2.5 mg
100 units = 5 mg
At 5 mg daily, a 10 mg vial lasts about 2 days
At 2.5 mg daily, a 10 mg vial lasts about 4 days
50 mg Vial Option
Vial
50 mg
Example BAC Water
2.0 mL
Concentration
25 mg/mL
Conversion
1 unit = 250 mcg
Dose Reference
10 units = 2.5 mg
20 units = 5 mg
40 units = 10 mg
Dose Reference
20 units = 2.5 mg
40 units = 5 mg
At 5 mg daily, a 50 mg vial lasts about 10 days
At 2.5 mg daily, a 50 mg vial lasts about 20 days
Example Injectable Research Framework
Lower Research Range
2.5 mg daily
Higher Research Discussion
5 mg daily
Route
Subcutaneous research format
Example Injectable Research Structure
Route
Subcutaneous research format
Frequency
Daily administration commonly discussed
Timing
Morning or divided AM/PM dosing discussed
Research Duration
Short-term phases commonly discussed
Example Injectable Research Phase
Initial Phase
Duration
First 1–2 weeks commonly used for tolerance assessment
Research Phase
Duration
Approximately 4–8 weeks commonly discussed
Injectable vs Oral Differences
Injectable and oral formats should not be directly converted.
Route changes absorption and exposure.
Injectable research formats are not equivalent to established oral use.
No human studies have confirmed the optimal injectable schedule.
Simple takeaway:Injectable 5-Amino-1MQ is generally discussed as a daily research format with shorter focused phases, while oral use is the more commonly discussed route. Neither has an approved human protocol.
Reconstitution Steps
Confirm vial capacity before selecting dilution volume.
Draw the correct amount of bacteriostatic water for the vial size
Inject slowly down the vial wall
Gently swirl, do not shake
Allow the compound to fully dissolve before use
Refrigerate after reconstitution
Simple takeaway:
Injectable 5-Amino-1MQ is usually discussed in the 2.5–5 mg daily range. A 10 mg vial works for short testing, while a 50 mg vial is more practical for a longer injectable research cycle.
Injectable 5-Amino-1MQ is usually discussed in the 2.5–5 mg daily range. A 10 mg vial works for short testing, while a 50 mg vial is more practical for a longer injectable research cycle.
5-Amino-1MQ Protocol
NNMT Inhibition → NAD+ Pathway Support → Metabolic Efficiency → Fat Metabolism Support
Evidence Note:
5-Amino-1MQ does not have an FDA-approved human dosing protocol. Most published research involves preclinical models, while injectable formats are primarily discussed in research settings. Human dosing, long-term safety, and optimal administration methods have not been established.
5-Amino-1MQ does not have an FDA-approved human dosing protocol. Most published research involves preclinical models, while injectable formats are primarily discussed in research settings. Human dosing, long-term safety, and optimal administration methods have not been established.
Oral Approach (Most Common)
Low Dose50 mg daily
Standard100 mg daily
Advanced150 mg daily
Split Dosing Option
50 mg AM + 50 mg PM
Low Dose
Starting Range
Dose50 mg daily
RouteOral
FrequencyOnce daily
Standard Range
Common Range
Dose100 mg daily
RouteOral
FrequencyOnce daily or split dosing
Advanced Range
Higher Range
Dose150 mg daily
RouteOral
FrequencyUsually split if needed
Simple approach:
5-Amino-1MQ is usually approached as a metabolic-support compound rather than a stimulant. Starting lower makes it easier to assess energy, appetite, and body-composition response before moving higher.
5-Amino-1MQ is usually approached as a metabolic-support compound rather than a stimulant. Starting lower makes it easier to assess energy, appetite, and body-composition response before moving higher.
How to Use 5-Amino-1MQ (Research Timing & Structure)
Important Evidence Note:
5-Amino-1MQ does not have an FDA-approved human dosing protocol. Most information comes from preclinical research and research-community discussion. The structure below is an educational framework and should not be interpreted as an established treatment guideline.
5-Amino-1MQ does not have an FDA-approved human dosing protocol. Most information comes from preclinical research and research-community discussion. The structure below is an educational framework and should not be interpreted as an established treatment guideline.
Most Discussed Route
Oral administration
Research Frequency
1–2x daily commonly discussed
Research Timeframe
4–8+ weeks commonly discussed
Timing
Morning or earlier in the day
Food
With or without food depending on preference
Timing Considerations
Earlier dosing is commonly discussed in research settings.
Some users prefer morning or afternoon timing due to possible effects on alertness.
Split dosing is sometimes discussed when dividing daily amounts.
No human study has established an ideal dosing schedule.
Research Context
Studied for NNMT inhibition and metabolic signaling pathways.
Often discussed during body-composition or metabolic-support phases.
Not considered an appetite suppressant like GLP-1 compounds.
Best viewed as an investigational metabolic compound rather than a quick fat-loss solution.
Simple Strategy
Use in Phases
5-Amino-1MQ is commonly discussed as a metabolic research compound used alongside nutrition, training, and body-composition goals.
Goal-Based Approach
Track individual response and reassess rather than assuming longer use provides additional benefit.
Alternative Delivery (Research Context)
Alternative Delivery Notes
Injectable versions exist in research-market formats.
Oral administration is the most commonly discussed format.
Oral and injectable amounts should not be directly converted.
Route changes exposure, absorption, and research context.
Simple takeaway:
Most discussion around 5-Amino-1MQ centers on oral use. Injectable formats are experimental research preparations and do not have a standardized human dosing protocol.
Most discussion around 5-Amino-1MQ centers on oral use. Injectable formats are experimental research preparations and do not have a standardized human dosing protocol.
Research Discussion vs Clinical Use
Research Discussion
Commonly Discussed Oral Range
50–100 mg daily
Research Focus
NNMT inhibition + metabolic pathways
Evidence Level
Preclinical / limited human data
Clinical Status
No approved human protocol
Time Between Research Phases
Metabolic Support Phase → Reassess → Reset → Consider Future Research Phase
Example Research Structure
Research Timeframe
4–8+ weeks commonly discussed
Time Between Phases
Individual reassessment period
Why reassess?
Because long-term human safety, optimal duration, and sustained effectiveness have not been established, continued use should be approached as an individual research consideration rather than a standardized cycle.
Because long-term human safety, optimal duration, and sustained effectiveness have not been established, continued use should be approached as an individual research consideration rather than a standardized cycle.
When to Reassess
No noticeable changes in goals being tracked
Unfavorable energy or tolerance changes
Continuing without a defined research goal
Monitoring During Use
Body-composition changes
Energy levels
Appetite changes
Weight trends
Training performance and recovery
Digestive tolerance
Potential Research Findings
Investigated for NNMT inhibition
May influence metabolic signaling pathways
Research interest includes cellular energy metabolism
Does not directly target appetite pathways like GLP-1 medications
Potential Side Effects & Unknowns
Limited long-term human safety data
Variable individual response
Possible fatigue or tolerance changes
Unknown effects from extended use
Important Notes
5-Amino-1MQ is a small molecule, not a peptide.
Research evidence is primarily preclinical.
No FDA-approved human dosing protocol exists.
It does not suppress appetite directly like GLP-1 compounds.
Injectable formats are research preparations and are not standardized.
Optimal route, duration, and long-term safety remain unknown.
Important Disclaimer
5-Amino-1MQ is an investigational compound and is not FDA-approved. This content is for educational purposes only.
Research & References
Primary Research
- Kraus D, Yang Q, Kong D, et al. Nicotinamide N-Methyltransferase Knockdown Protects Against Diet-Induced Obesity. Nature. 2014.
- Neelakantan H, Vance V, Wetzel MD, et al. Selective and Membrane-Permeable Small Molecule Inhibitors of Nicotinamide N-Methyltransferase Reverse High Fat Diet-Induced Obesity in Mice. Biochemical Pharmacology. 2018.
- Brachs S, Polack J, Brachs M, et al. Genetic Nicotinamide N-Methyltransferase (Nnmt) Deficiency in Male Mice Improves Insulin Sensitivity in Diet-Induced Obesity but Does Not Affect Glucose Tolerance. Diabetes. 2019.
- Aksoy S, Szumlanski CL, Weinshilboum RM. Human Liver Nicotinamide N-Methyltransferase: cDNA Cloning, Expression, and Biochemical Characterization. Journal of Biological Chemistry. 1994.
Comments
Post a Comment